Fresenius Kabi Files EU Pegfilgrastim

‘Milestone’ Biosimilar Submission Comes Ahead Of Planned Launch In 2021

 
• By Dave Wallace

Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.

Fresenius Kabi
Fresenius Kabi has seen its biosimilar pegfilgrastim filing accepted for EMA review • Source: Shutterstock

More from Biosimilars

More from Products